Advancing RNA medicine: This is what a new research network, in which JMU is involved, wants to achieve.
Advancing RNA medicine: This is what a new research network, in which JMU is involved, wants to achieve. The German Federal Ministry of Economics and Technology is funding a joint project to research efficient and safe special lipids for mRNA drugs with almost 13 million euros. Partners in the research alliance are the universities of Jena, Würzburg and Dortmund, the start-up company NGP Polymers in Jena, and the companies Bayer, Evonik and ISAR Bioscience. Since the Corona pandemic, the usefulness of ribonucleic acids (RNA) or messenger RNA (mRNA) for the production of highly effective vaccines has been undisputed. Now the partners from industry and science want to investigate whether other new drugs can also be developed on this basis, as well as whether the few allergic reactions associated with vaccinations can be reduced. Developing novel special lipids for RNA drugs . Compared to RNA-based vaccines, new compositions of the drugs are needed to deliver the new medications to the disease site in a targeted manner.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
